| Literature DB >> 28379390 |
Praveen Kumar Dubey1, Kazuya Masuda1, Kishan Kumar Nyati1, Mohammad Mahabub -Uz Zaman1, Jaya Prakash Chalise1, David Millrine1, Wang Kai1, Barry Ripley1, Tadamitsu Kishimoto1.
Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the major causes of death worldwide due to acute inflammation in the lung. AT-rich interactive domain-containing 5a (Arid5a) is an RNA-binding protein involved in inflammatory autoimmune disease through post-transcriptional control of Il6, Stat3 and Tbx21 gene expression. We found that Arid5a-deficient mice were highly refractory to bleomycin (BLM)-induced lethality. Arid5a deficiency suppressed lung pathology, cytokine production (especially, IL-6), and clinical symptoms in BLM-treated mice. Production of reactive oxygen species (ROS) in response to BLM-induced cellular damage was inhibited in Arid5a-deficient mice, potentially affecting the level of oxidized 1-palmitoyl-2-arachidonoyl-phosphaticylcholine (OxPAPC) production. OxPAPC, which is supposed to be a TLR4/TLR2 ligand, stimulated expression of the Arid5a and Il6 genes. Thus, reduction of ROS production in Arid5a-deficient mice could mitigate OxPAPC production, which in turn decreases IL-6 production in vivo due to dysregulated post-transcriptional regulation by loss of Arid5a. Therefore, the control of Arid5a expression represents a potential therapeutic target for treatment of ALI and ARDS. © The Japanese Society for Immunology. 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: IL-6; OxPAPC; ROS; acute lung injury; acute respiratory distress syndrome
Mesh:
Substances:
Year: 2017 PMID: 28379390 DOI: 10.1093/intimm/dxx004
Source DB: PubMed Journal: Int Immunol ISSN: 0953-8178 Impact factor: 4.823